AI assistant
AstraZeneca Pharma India Ltd. — Regulatory Filings 2019
Nov 27, 2019
60656_rns_2019-11-27_0cb782e7-38b8-4265-9997-467d8b5dad13.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
==> picture [28 x 41] intentionally omitted <==
AstraZeneca
November 27, 2019
==> picture [86 x 68] intentionally omitted <==
==> picture [78 x 6] intentionally omitted <==
----- Start of picture text -----
Bdnglng scltnc• lo paU1nti. 1lnc• 1979
----- End of picture text -----
The Manger - Listing BSE Limited
Corporate Relationship Dept., I s1 Floor, New Trading Ring Rotunda Building, P J Towers, Dalal Street, Fort, Mumbai 40000 I
National Stock Exchange of India Ltd.
Exchange plaza, 5th Floor, Plot No.C/1, G Block Bandra-Kurla Complex, Bandra (E), Mumbai 400051
Dear Sir(s),
Sub: Disclosure of Related Party Transactions
Ref: Scrip Code - BSE: 506820, NSE: ASTRAZEN
Pursuant to the provisions of Regulation 23 (9) of SEBI (Listing Obligations and Disclosure Related Requirements) Regulations, 2015 as amended, we enclose herewith the disclosure of records. Party Transactions for half year ended September 30, 2019 for your information and
For AstraZeneca Pharma India limited
l �0,--;ra(p Rudra ; Company Secretary & Legal Counsef'�v • - - ---
TEL : +91 80 6774 9000
TEL : +91 eo 6774 8000 FACTORY TEL : +91 80 6774 9000 12th Mile on Bellary Road FAX : +91 80 6774 8857 Venkatala, Kattigenahalli Village FAX : +91 80 2846 2208 CIN : L24231KA1979PLC003563 Yelahanka Bangalore - 560 063 +91 80 6774 9628 WEB INDIA
CORPORATE & REGD. OFFICE AstraZeneca Pharma India Ltd. P. B. No. 4525, Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore - 560 045, INDIA
WEB : www.astrazeneca.com/india
AstraZeneca Pharma India Limited
Disclosure of related party transaetions l'or the half year ended JO September, 2019
In pursuance with Regulation 23(9) ofSEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulations. 2018 (All amounts in Rs.million. except per share and sharc data)
-
(i) Names or related parties and related party relationship
-
(a) Related parties where control exists and/or where transactions have occurred:
| Name or the entity | Name of relationship |
|---|---|
| I lolding Company | AstraZeneca Pharmacculicals AB, Sweden |
| Holding Company of AstraZeneca | |
| Pharmaceulicals /\8, Sweden | AstraZeneca Al3, Sweden |
| Holding Company of /\slraZcneca AB, Sweden | AstraZeneca Treasury Limi1ccl, United Kingdom |
| Ul1ima1e Holding Company | AslraZcncca Pie, United Kingdom |
| Fellow subsidiaries wilh whom lhe company had | /\slraZcneca Singapore Pie Lid, Singapore |
| 1ransac1ions during lhc year | /\slraZcneea India Private Limited, India |
| AstraZeneca Phannaceuticals LP, USA | |
| AstraZeneca UK Limited, United Kingdom | |
| P.T. AstraZeneca Indonesia | |
| AslraZencca Ply Ltd, Australia | |
| Employees' Benefil Plans | AstraZeneca Pharma India Limited Employees Gratuity Fund Trusl |
| AstraZeneca Phanna India Limited Management Staff Provident Fund Trusl | |
| AstraZeneca Phann a India Limited Management Staff Supcranmmlion Fund Trust | |
| b) Key Management Personnel | |
| - Managing Director | Mr. Gagandccp Singh Bcdi |
| - Director and Chief Financial Officer | Mr. Rajesh Marwaha |
| - Non-Executive Directors | Mr. I an John Parish |
| Ms. Weiying Sarah Wang | |
| c) Independent Directors | Mr. Narayan K Seshadri |
| Ms. Revathy /\shok | |
| Ms. Kimsuka Narasimhan |
==> picture [76 x 74] intentionally omitted <==
AstraZeneca Pharma India Limited
Disclosure or related party transactions fur the hal r year ended JO September, 2019
| AstraZeneca Pharma India Limited Disclosure or related party transactions fur the hal r year ended JO September, 2019 |
AstraZeneca Pharma India Limited Disclosure or related party transactions fur the hal r year ended JO September, 2019 |
|
|---|---|---|
| In pursnanee with Regulation 23(9) of SfWI (Listing Ohligations and Disclosure Requirements) (Amendments} Rcgnlatious. | 2018 | |
| (All | nmounts in Rs.million, except per share and share data) | |
| (ii) | Details of the trn saetions with the related parties during the period 01 April 2019 lo JO September 2019: | |
| l'urchasc of materials and traded goods | ||
| AstraZeneca UK Limited, United Kingdom | 1,220.1 | |
| AstraZeneca AB, Sweden | 103.2 | |
| Payment Inwards reimbnrscmenl or expenses | ||
| AstraZeneca UK Limited, United Kingdom | 8.2 | |
| AstraZeneca Ply Llcl, Australia | 2.0 | |
| Sale or services | ||
| AstraZeneca AB, Sweden | 187.0 | |
| Recovery or reimbursable expenses | ||
| AstraZeneca UK Limited, United Kingdom | 29.8 | |
| AstraZeneca AB, Sweden | 33.7 | |
| P.T. AstraZeneca Indonesia | 14.6 | |
| AstraZeneca Singapore Pte Lld, Singnpore | 4.6 | |
| AstraZeneca Pharmaceuticals LP, USA | 6.6 | |
| Contribution In Trusts | ||
| AstraZeneca Pharma lndin Limited Management Staff Superannuation Fund Trust |
6.3 | |
| (iii) | (a) T ransactions with Key i\lanagemcnl Personnel | |
| Salary and perquisites | ||
| Short-term employee benefits | 37.6 | |
| Long-term employee benefits | 7.4 | |
| Post employment benefits | I 5.1 | |
| Employee share compensation expenses | 2.3 | |
| 62.J | ||
| {iii) (b) Transactions with Independent Directors | ||
| Silling fees paid to independent directors | 1.7 | |
| (iv) | Details ofbnlanccs receivable from nnd payable to related parties as at JO September, 2019 arc as follows: | |
| Other current finnncial assets | 35.5 | |
| AstraZeneca UK Limited, United Kingdom | 28.0 | |
| AstraZeneca Pharmaceuticals LP, USA | 2.8 | |
| AstraZeneca Singapore Pte Ltd, Singapore | 2.1 | |
| P.T. AstraZeneca Indonesia | 2.7 | |
| Trade receivables | 121.1 | |
| AstraZeneca AB, Sweden | 121.1 | |
| Trade payables | 690.9 | |
| AstraZeneca UK Limited, United Kingdom | 614.4 | |
| AstraZeneca AB, Sweden | 74.S | |
| AstraZeneca Pty Ltd, Australia | 2.0 |
==> picture [75 x 74] intentionally omitted <==